A carregar...
The role of carfilzomib in relapsed/refractory multiple myeloma
Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and a...
Na minha lista:
| Publicado no: | Ther Adv Hematol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8191071/ https://ncbi.nlm.nih.gov/pubmed/34163580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20406207211019612 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|